menu
    • menu
    [{"orgOrder":0,"company":"National University Health System, Singapore","sponsor":"National Medical Research Council, Singapore | NattoPharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SINGAPORE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Menaquinone-7","moa":"Pregnane X receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National University Health System, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National University Health System, Singapore \/ National Medical Research Council, Singapore | NattoPharma","highestDevelopmentStatusID":"8","companyTruncated":"National University Health System, Singapore \/ National Medical Research Council, Singapore | NattoPharma"},{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Partnership","leadProduct":"Menaquinone-7","moa":"||Pregnane X receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SunWay Biotech \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"15","companyTruncated":"SunWay Biotech \/ Gnosis by Lesaffre"},{"orgOrder":0,"company":"Aristotle University Of Thessaloniki","sponsor":"NattoPharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GREECE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Menaquinone-7","moa":"Pregnane X receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Aristotle University Of Thessaloniki","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aristotle University Of Thessaloniki \/ NattoPharma","highestDevelopmentStatusID":"1","companyTruncated":"Aristotle University Of Thessaloniki \/ NattoPharma"},{"orgOrder":0,"company":"NattoPharma","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Menaquinone-7","moa":"Pregnane X receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"NattoPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NattoPharma \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"15","companyTruncated":"NattoPharma \/ Gnosis by Lesaffre"}]

    Find Clinical Drug Pipeline Developments & Deals for Menaquinone-7

    Menu

    Menaquinone-7

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SunWay Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SunWay Biotech

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menaquinone-7,Ankascin 568-R

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Gnosis by Lesaffre

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            SunWay Biotech and Gnosis Launch MenaQ7® Metabolic Featuring ANKASCIN® 568-R Ingredient

                            Details : The partnership aims to launch SunWay's inaugural product, MenaQ7® Metabolic, featuring two key active ingredients, MenaQ7® Vitamin K2 as MK-7 and ANKASCIN® 568-R.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            March 14, 2024

                            Lead Product(s) : Menaquinone-7,Ankascin 568-R

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Gnosis by Lesaffre

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aristotle University Of Thessaloniki

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aristotle University Of Thessaloniki

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menaquinone-7

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Sponsor : NattoPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis

                            Details : Menaquinone-7 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Vitamin K Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            May 25, 2021

                            Lead Product(s) : Menaquinone-7

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Sponsor : NattoPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NattoPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NattoPharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menaquinone-7

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Gnosis by Lesaffre

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Gnosis by Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharma

                            Details : This acquisition brings together globally recognized vitamin K2 brands vitaMK7® and MenaQ7® and allows Gnosis by Lesaffre to offer to the market the most complete portfolio of solutions, adapted to each market need and able to satisfy all customers.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            May 25, 2021

                            Lead Product(s) : Menaquinone-7

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Gnosis by Lesaffre

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            National University Health System, Singapore

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            National University Health System, Singapore

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Menaquinone-7

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : National Medical Research Council, Singapore | NattoPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment to Reduce Vascular Calcification in Hemodialysis Patients Using Vitamin K

                            Details : Menaquinone-7 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Vascular Calcification.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            August 17, 2016

                            Lead Product(s) : Menaquinone-7

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : National Medical Research Council, Singapore | NattoPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth